Pneumatosis intestinalis and porto-mesenteric venous gas: a multicenter study

Marta Della Seta1, Roman Kloeckner2, Daniel Pinto dos Santos3, Thula Cannon Walter-Rittel1, Felix Hahn2, Jörn Henze3, Annika Gropp1, Johann Pratschke4, Bernd Hamm1, Dominik Geisel1 and Timo Alexander Auer1,5*

Abstract

Background: Estimating the prognosis of patients with pneumatosis intestinalis (PI) and porto-mesenteric venous gas (PMVG) can be challenging. The purpose of this study was to refine prognostication to improve decision making in daily clinical routine.

Methods: A total of 290 patients with confirmed PI were included in the final analysis. The presence of PMVG and mortality (90d follow-up) were evaluated with regard to the influence of possible risk factors. Furthermore, a linear estimation model was devised combining significant parameters to calculate accuracies for predicting death in patients undergoing surgery by means of a defined operation point (ROC-analysis).

Results: Overall, 90d mortality was 55.2% (160/290). In patients with PI only, mortality was 46.5% (78/168) and increased significantly to 67.2% (82/122) in combination with PMVG (median survival: PI: 58d vs. PI and PMVG: 41d; \( p < 0.001 \)). In the entire patient group, 53.5% (155/290) were treated surgically with a 90d mortality of 58.8% (91/155) in this latter group, while 90d mortality was 51.1% (69/135) in patients treated conservatively. In the patients who survived > 90d treated conservatively (24.9% of the entire collective; 72/290) PMVG/PI was defined as "benign"/reversible. PMVG, COPD, sepsis and a low platelet count were found to correlate with a worse prognosis helping to identify patients who might not profit from surgery, in this context our calculation model reaches accuracies of 97% specificity, 20% sensitivity, 90% PPV and 45% NPV.

Conclusion: Although PI is associated with high morbidity and mortality, „benign causes” are common. However, in concomitant PMVG, mortality rates increase significantly. Our mathematical model could serve as a decision support tool to identify patients who are least likely to benefit from surgery, and to potentially reduce overtreatment in this subset of patients.

Keywords: Pneumatosis intestinalis, Porto-mesenteric venous gas, PMVG, Bowel ischemia, Sepsis

Key points

Key Point 1: The coincidence of porto-mesenteric venous gas (PMVG) and pneumatosis intestinalis (PI) is indicative for a significant increase of mortality.

Key Point 2: PMVG, COPD, sepsis and a low platelet count were found to correlate with a worse prognosis helping to identify patients who might not profit from surgery.
Key Point 3: Our linear regression model reached a specificity of 97% in predicting death for patients undergoing surgery and might thus be helpful in clinical decision-making.

Introduction

Pneumatosis intestinalis (PI) is defined as the presence of gas within the submucosal or mucosal wall of the intestine [1]. PI was first described anatomically in 1730 by Duvernoy and named nearly hundred years later by Mayer as pneumatosis cystoides intestinalis [1–3]. PI is a radiographic or histopathologically verified phenomenon, rather than a clinical diagnosis with potentially life-threatening consequences for the patient. The aetiology of PI is complex. But overall, three causes have been identified as the source/origin of gas within the intestinal wall:

1. gas formed in the intestine, i.e. luminal gas [4].
2. gas-producing bacteria [5, 6].
3. gas from the respiratory system [7–9].

Aetiology may range from ischemia or bowel obstruction to sepsis and many other conditions. Apart from these clearly life-threatening pathologies, benign/reversible causes like respiratory disorders and/or unfavourable drug related side effects—e.g. chemotherapy-associated—have been reported [10–12]. The clinical presentation can be unspecific, but the most common symptoms involve abdominal pain, diarrhoea, bloody stools, fever, and shock [1, 13, 14]. Upon presentation, a clinical examination must be performed, and abdominal x-ray can be helpful. However, in clinical reality, computed tomography (CT) is the modality of choice for diagnosing PI [3, 15].

Yet, the role and prognostic relevance of gas ascending into the liver, causing porta-mesenteric venous gas (PMVG) remains unclear. PMVG has been both described as linked to increased mortality as well as a reversible phenomenon [1, 10, 16–19] (Fig. 1). For most “unexperienced” radiologists and surgeons, the pattern of PI and gas in the portal venous system is indicative of a potentially irreversible intestinal infarction and associated with a poor prognosis. Although PI and PMVG have been discussed for decades, there is little to no comprehensive evidence-based data on PI and especially PMVG. Most data available on benign and reversible causes of PVMG is based on case reports or case series [10, 12].

Patients with PI and PMVG can have distinctly different prognoses. In clinical practice, it can be challenging to decide upon further treatment of patients with PI, even for experienced clinicians. The purpose of this
study was to refine prognostication for these patients to improve decision-making in daily clinical routine with a special focus on patient outcome after surgical treatment.

Methods and material

Patients

Our institutional review board approved this retrospective multicentre study (registration number EA2/238/17). The study protocol conforms to the ethical guidelines of the 2002 Declaration of Helsinki. Informed consent was waived due to the retrospective nature of this study. The study was conducted at three tertiary care university medical centres (University Medicine Berlin, University Medical Centre Mainz, and University Hospital of Cologne). The respective radiological information systems (RIS) were searched from the readers for reports filed during the timespan of January 2008 to January 2018, and contained the following keywords: pneumatisis, pneumatosis intestinalis, gas in the bowel wall, venous gas, gas in the portal vein and intramural gas (Fig. 2). Where available, pathology and surgery reports were retrieved from the hospital information systems. The diagnosis of PI was confirmed by a board-certified radiologist after re-reading the respective imaging studies. To increase quality and to avoid false positives, all cases were re-read by two radiologists in consensus at every centre; one of each with at least ten years of abdominal CT experience (University Medicine Berlin: D.G and M.D.S; University Medical Centre Mainz: R.K and F.H; University Hospital of Cologne: D.P.D.S and J.H). Re-reading was performed to confirm the presence of gas within the gastrointestinal wall, as opposed to luminal gas, i.e. pseudopneumatosis phenomenon (false positive).

Mortality and overall survival (OS) were evaluated. OS was determined within a 90-day follow-up after the initial CT examination. To control for selection-bias, the following qualitative and quantitative risk factors were evaluated:

Qualitative parameters

Age, sex (male and female), presence of PMVG, sepsis, vascular disease defined by varying degrees of stenosis (50–75%, 76–100%) of the superior or inferior mesenteric artery (AMS and AMI) or the coeliac trunk, underlying oncologic diagnosis, COPD, cardiovascular disease, presence of bowel obstruction (large vs. small bowel obstruction), decreased bowel wall enhancement and the therapeutic use of steroids.

Fig.2 Flowchart showing the patient selection process, mortality and survival rates
Quantitative parameters
Length of the PI-affected gastrointestinal segment (from 0 to 100 cm in increments of 10 cm), laboratory parameters including CRP, procalcitonin (PCT), platelet count, and lactate.

Imaging acquisition
All patients were examined with multislice CT scanners and underwent single or multiphase CT examinations (arterial, and/or portal-venous and/or delayed phase). At the first institution (University Medicine Berlin) patients were either examined using a 128-multislice (Revolution HD and Revolution EVO, GE Healthcare, Milwaukee, WI, USA) or one of two 64-multislice CT scanners (Somatom Sensation 64, Siemens Medical Systems, Forchheim, Germany). All patients received a non-ionic intravenous contrast agent (either Ultravist 370, Bayer Schering, Berlin, Germany, Xenetix 350, Guerbet, Villepinte, France or Imeron 400, Bracco, Milan, Italy). At the second institution, patients were examined with either a 256-multislice CT scanner or by a 64-multislice scanner (Philips iCT and Brilliance, Philips, Amsterdam, Netherlands). All patients received a non-ionic intravenous contrast agent (Imeron 400, Bracco, Milan, Italy). At the third institution, patients were examined with either a 256-multislice CT scanner (Philips iCT, Philips, Amsterdam, Netherlands) or a 128-multislice scanner (Philips IQon, Philips, Amsterdam, Netherlands). All patients received a non-ionic intravenous contrast agent (Accupaque 350, GE Healthcare, Milwaukee, WI, USA). Scan direction was craniocaudal in all institutions.

Statistical analysis
All statistical analyses were performed using XLSTAT (Version 2011.0.01; Addinsoft SARL, New York, USA) and with R 3.5.1 using RStudio 1.1.463; R Core Team (2018) [20]. Survival plots/Kaplan–Meier Curves were calculated and designed using R 3.5.1 with RStudio and help of the ‘survival’ package [21]. Contingency tables were used for statistical results with proportional distributions. OS was estimated using the Kaplan–Meier analysis and compared using the Logrank test. The Cox proportional hazard model was used for multivariate analyses to evaluate the influence of each risk factor on overall survival. A multivariate logistic regression model was used to test for influence of each risk factor on dichotomized variables (overall mortality, “benign” PI etc.). A p-value of less than 0.05 was considered statistically significant. Finally, a generalized linear / logistic regression model was built using the subset of patients who did not undergo surgery. We devised a statistical calculation model to predict death in surgically treated patients. A random sample of 100 patients from the conservatively treated cohort was used to fit the model. For random sampling a classified random sampling was performed using R’s “caret” package. The remaining 31 conservatively treated patients were used to verify the model’s performance. We then applied the model to the surgically treated patient cohort. We set an operating point for prediction of death with greater than 95% specificity to identify patients with an increased mortality risk despite surgical treatment. Accuracies were given as sensitivity, specificity, positive and negative predictive values (PPV/NPV).

Results
Demographics
A total of 290 patients (119 female and 171 male, mean age: 66.7, range: 18–92 years) with radiologically confirmed PI were finally included; concomitant PMVG was detected in 42% (122/290). PI was associated with radiologically suspected ischemia (decreased bowel wall enhancement) in 32.4% (94/290) and with mechanical (n=43) or non-mechanical (n=67) bowel dilatation in 38.0% (110/290). Of the patients with a mechanical bowel obstruction, 42% (18/43) had small bowel and 58% (25/43) large bowel obstruction. Mechanical bowel obstruction was observed significantly more often in the “PI only”- subgroup (p=0.004), while the location (small vs. large bowel) did not differ significantly. Sepsis was documented in 26.9% (78/290) of patients. Surgery was performed in 53.5% (155/290) of all patients (Fig. 1). Sepsis was significantly more prevalent in patients with coinciding PMVG (p=0.010), compared to the “PI only”-group, all other distributions showed no significant differences (Table 1).

All patients
Overall mortality for all patients within the 90d follow-up was 55.2% (160/290; median OS 51d ± 3.3; 95% CI 46.1–55.7). Mortality was 46.5% (78/168) in patients with PI only and increased significantly to 67.2% (82/122) in the presence of PMVG (p<0.001) (Fig. 2). Accordingly, Kaplan–Meier analyses showed a significantly longer OS for patients with PI only (58d ± 3.1; 95% CI 52.4–64.5) compared to patients with PI and PMVG (41d ± 3.8; 95% CI 33.1–48.0) (p<0.001) (Fig. 3).

Subgroup analyses
Surgical treatment
The collective was further subdivided into subgroups depending on treatment. Surgery was performed in 53.5% of all patients (155/290), mortality in this cohort was 58.8% (91/155) (50d ± 3.3; 95% CI 44.0–56.5). In patients with PI only (85/155) mortality was 54.1% (46/85) (median OS 56d ± 4.4 SD; 95% CI 47.1–64.4) and
increased to 64.3% (45/70) (median OS 43d ± 5.0 SD; 95% CI 33.3–56.7) in the presence of PMVG (155/290) (p < 0.096). A pathology report was available in 62.0% (96/155) of these surgically treated patients. Intestinal ischemia was diagnosed in 67.5% (66/96), while in 32.5% (30/96) the pathologist found no sign of ischemia or intestinal infarction. Mortality and OS did not differ significantly between these subgroups (ischemia subgroup: 49d ± 5.0 SD; 95% CI 39.8–59.0) vs. non-ischemia subgroup: 61d ± 6.9 SD; 95% CI 52.6–69.9) (p = 0.304) (Fig. 3).

Conservative treatment

46.5% of all patients (135/290) were managed conservatively (i.e. without surgery). Mortality in this cohort was 51.1% (69/135) (52d ± 3.7; 95% CI 44.8–59.2). In patients with PI only mortality was 38.6% (38/99) (median OS 51d ± 4.4 SD; 95% CI 52.6–69.9) and increased significantly to 71.2% (37/52) (median OS 37d ± 5.9 SD; 95% CI 25.750.0) in the presence of PMVG (39/55) (p < 0.001). Patients were further divided in two different subgroups. The first included patients who were treated conservatively and survived the 90d follow-up (n = 72) (“benign” cohort). The second group included patients who were unfit for surgery and died within the 90d follow-up (n = 63) (“deceased” cohort). Median survival for patients who died within the 90d follow-up was 9d ± 2.1 (SD; 95% CI 4.7–13.1). The prevalence of PMVG was significantly higher (p < 0.05) in the “deceased” cohort 52.2% (33/63) compared to the “benign” cohort (27%; 19/72) (Figs. 2 and 3). Detailed results can be found in Table 1.

Table 1  Descriptive patient characteristics (clinical parameters, overall mortality and pathologies)

| Characteristics                  | Entire population (n = 290) | Subgroup—PI only (n = 168) | Subgroup—PI and PMVG (n = 122) | p-value |
|----------------------------------|-----------------------------|-----------------------------|---------------------------------|---------|
| Age—years                        |                             |                             |                                 |         |
| Mean—range                       | 66.7—18–92                  | 66.1—18–92                  | 67.5—19–90                      | >0.05   |
| Gender (%)                       |                             |                             |                                 |         |
| Female                           | 40.3 (119)                  | 44.6 (75)                   | 36.1 (44)                       |         |
| Male                             | 59.7 (171)                  | 55.4 (93)                   | 63.9 (78)                       |         |
| Overall mortality (%)            | 55.2 (160)                  | 46.5 (78)                   | 67.2 (82)                       |         |
| 90d follow up (d)                | 51                          | 58                          | 41                              | <0.001  |
| Subgroup analyses                |                             |                             |                                 |         |
| Surgery cohort (%)               | 58.5 (97)                   | 54.1 (46)                   | 64.4 (45)                       |         |
| 90d follow up                    | 50                          | 56                          | 43                              | 0.096   |
| Conservatively treated cohort (%)| 51.1 (63)                   | 38.6 (32)                   | 71.1 (37)                       | <0.001  |
| 90d follow up (d)                | 52                          | 61                          | 37                              |         |
| Aetiology (%)                    |                             |                             |                                 |         |
| Ischemia                         | 32.4 (94)                   | 30.1 (52)                   | 34.4 (42)                       | 0.611   |
| Bowel obstruction                | 38.0 (110)                  | 53.6 (59)                   | 46.4 (51)                       | 0.393   |
| Mechanic                         | 40.0 (43)                   | 52.5 (31)                   | 23.5 (12)                       | 0.004   |
| Small bowel                      | 42.0 (18)                   | 32.3 (10)                   | 66.6 (8)                        | 0.058   |
| Large bowel                      | 58.0 (25)                   | 67.7 (21)                   | 33.3 (4)                        | 0.058   |
| Non-mechanic                     | 60.5 (67)                   | 47.5 (28)                   | 66.5 (39)                       | 0.004   |
| Sepsis                           | 26.9 (78)                   | 21.4 (36)                   | 34.4 (42)                       | 0.016   |

p < 0.05 was considered statistically significant

PI: pneumatosis intestinalis; PMVG: porto-mesenteric venous gas; OP: Operation

Comprehensive risk profile analysis

In a second step, the possible influence of several risk factors on survival were calculated by means of multivariate regression models (Table 2).

Cox proportional hazard model

The following parameters were associated with decreased overall survival: old age (p = 0.041; HR: 1.01 / 95% CI 1.00–1.03); sepsis (p = 0.005; HR: 1.82 / 95% CI 1.20–2.75); coeliac/mesenteric artery stenosis of 76–99% (p = 0.010; HR: 2.00 / 95% CI 1.17–3.26), COPD (p = 0.002; HR: 1.92/95% CI 1.28–2.87), length of intestine affected by PI > 1 m (p = 0.007; HR: 2.07 / 95% CI 1.25–3.50), elevated CRP-count (p = 0.008; HR: 1.00 / 95% CI 1.00–1.00), elevated serum lactate levels (p = 0.042; HR: 1.00 / 95% CI 1.00–1.05), and decreased platelet count (p = 0.001; HR: 1.00 / 95% CI 1.00–1.01). Furthermore, elevated PCT showed a trend
towards shortened survival but did not reach statistical significance \((p = 0.053, \text{HR: } 1.01 / 95\% \text{ CI } 1.00–1.03)\) (Table 2).

**Multivariate logistic regression model**

The following parameters were associated with reversible / "benign" PI: the absence of PMVG \((p < 0.042)\), the absence of COPD \((p < 0.017)\) and low CRP levels \((p = 0.006)\). All other risk factors had no significant influence on reversibility of PI in the conservatively managed group. A low platelet count was found to be associated with fatal outcome with the group of patients who were managed conservatively/i.e. non-surgically \((p < 0.001)\).

**Multivariate estimation model**

As abovementioned, the following parameters were statistically significant for a decreased OS: PMVG, COPD, sepsis and low platelet count.

All other results and parameters out of the multivariate risk factor analysis are displayed in Table 2.

After subdividing patients into two cohorts, a surgically treated and conservatively treated cohort, in the no-surgery cohort, the parameters were re-tested again by means of a training set to predict death. P-values generated from the training set were as follows: PMVG: \(p = 0.023\), COPD: \(p = 0.083\), sepsis: \(p = 0.006\) and thrombocytes: \(p = 0.003 – AlIC: 0.818\) (Fig. 4A). In a second step, we used the model to analyse the surgery-cohort with these parameters to predict death and
calculated an AUC of 0.689 (Fig. 4B). We identified and defined a point on the curve with a specificity of 95%. To reach this specificity a sensitivity of 20% had to be accepted with a threshold of 1.8 (Fig. 4C). Accuracies generated by this model to predict death were as follows: 97% specificity, 20% sensitivity, PPV 90%, NPV 45%. When dividing the cohorts according to the calculated threshold, resulting Kaplan–Meier curves also showed significant differences in overall survival \( p < 0.001 \) (Fig. 4D).

**Discussion**

Prognostication in patients with PI and PMVG is challenging. This study confirms PI as a life-threatening diagnosis with an associated mortality rate of 54.1%. In the presence of PI and concomitant PMVG, mortality increases to 68.2%. Especially the presence of infection and ischemia correlate with a worse prognosis. Nevertheless, patients with “benign”, i.e. reversible PI are common (25% in this study). The mathematical model we introduce helped us to pinpoint risk factors (PMVG, COPD, platelet count, sepsis) to identify patients with an increased mortality risk.

While the true incidence of PI is unknown, PI is diagnosed in day-to-day radiologic routine and its prognostic value remains unclear; especially in a setting with coincident PMVG. Some case reports have been published claiming that PMVG might have reversible causes, while others suggest PMVG has a dismal prognosis \([22]\). The physical examination of the patients plays a key role in management and triage, as patients with signs of peritonitis or suspicion of intestinal ischemia and perforation are candidates for explorative surgery. However, other parameters to assist clinical decision-making and prognostic factors to potentially differentiate fatal from benign/ reversible PI are currently lacking. There are some factors, such as elevated serum lactate that seem to be associated with an increased mortality, mainly due to the worse outcome in patients with ischemia, albeit with a low level of evidence (Figs. 5A–D and 6A–D) \([23–25]\).

With 290 patients, this multicentre trial is one of the largest of its kind since the introduction of CT scanners.

### Table 2 Comprehensive multivariate risk factor analysis

| Risk factor / parameters | Cox-Regression Entire population(n = 290) | Benign subgroup(n = 72) | Multivariate Regression Deceased subgroup(n = 63) | Multivariate Regression p-value |
|--------------------------|------------------------------------------|-------------------------|-----------------------------------------------|--------------------------------|
| Qualitative parameters:  |                                          |                         |                                               |                                |
| Sex                      | 0.626                                    | 0.218                   |                                               | 0.464                          |
| Female                   | 119                                      | 26                      |                                               |                                |
| Male                     | 171                                      | 46                      |                                               |                                |
| PMVG (present):          | 122                                      | 19                      | 0.042                                         | 33                             |
| Sepsis (present):        | 78                                       | 10                      | 0.033                                         | 0.108                          |
| Vascular disorders:      |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| 50–75%                   | 28                                       | 7.75                    | 8                                              | 0.559                          |
| 76–99%                   | 34                                       | 0.010                   | 4                                              | 0.467                          |
| Occlusion                | 28                                       | 0.137                   | 5                                              | 0.369                          |
| Oncologic disease:       |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| Cardiovasc. disease:     |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| COPD (present)           |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| Bowel-obstruction:       |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| Steroids therapy:        |                                          |                         |                                               |                                |
| Present (present)        |                                          |                         |                                               |                                |
| Length                   |                                          |                         |                                               |                                |
| 10–90 cm                 | 236                                      | 0.097–0.904             | 62                                             | 0.039                          |
| > 100 cm                 | 54                                       | 0.007                   | 10                                             | 0.039                          |
| Quantitative parameters: |                                          |                         |                                               |                                |
| Age                      |                                           | 0.041                   | 66.0 ± 14.7                                    | 64.6 ± 16.1 referees 654      |
| CRP (mg/l)               | 129.4 ± 125.6                            | 0.008                   | 80.3 ± 96.5                                    | 136.9 ± 118.9 refereed 555     |
| PCT (μg/l)               | 8.2 ± 6.1                                | 0.053                   | 2.7 ± 4.7                                      | 11.7 ± 15.0 referees 339       |
| Lactate                  | 32.6 ± 39.9                              | 0.042                   | 26.5 ± 38.0                                    | 46 ± 63.9 referees 540         |
| Platelets                | 218.1 ± 141.6                            | < 0.001                 | 231.7 ± 116.2                                  | 122.8 ± 115.0 referees 001     |

\( p < 0.05 \) was considered statistically significant
The mortality rates described in this study are in line with current studies. Lassandro et al. reported a 30.4% overall mortality for PI and 50% for PI in combination with PMVG in 102 patients [26]. Treyaud et al. reported an overall mortality of 41.6% in 149 patients. We found that the presence of PMVG correlated with ischemia, which is in line with Treyaud et al. However, Treyaud et al. defined decreased bowel wall enhancement on CT as “ischemia”, if—like in most cases—pathology reports were not available [22]. In our study, the pathology report was used as the gold standard for ischemia, which we then used to correlate ischemia with the presence of PMVG.

Despite the high mortality rates reported in this study, and the fact that survival was even lower in the presence
Fig. 5  A-D is showing an arterial phase contrast enhanced CT with axial slices (A, B) and coronar reconstructions with an extensive PI and PMVG in a 68-year-old patient with an acute embolism (yellow arrow in c) of the superior mesenteric artery (A, C) suffering from ischemia of the small bowel, transverse and ascending colon. Apart from cystic air bubbles within the intestinal wall, note the presence of gas in the mesenteric veins (PVMG) (B/b) and portal veins of the left upper liver lobe (D/d). Explorative laparotomy showed extensive intestinal necrosis. The patient died within 24 h after the CT-examination.

Fig. 6  A-D is showing an arterial phase contrast enhanced CT with axial slices (A, B) and coronar reconstructions with a fulminant PI and PMVG (B, D) in a 85 year-old patient with sepsis. Note the presence of gas within in the intestinal wall the entire small and large intestine, as well as the oesophagus (C), caused by bacterial enteritis after surgical fixation of an acetabular hip fracture on the right (A) with pelvic perforation of the osteosynthesis. The patient died within 24 h after the CT-examination.
of PMVG, we identified 72 patients who survived with non-surgical management. Although the prevalence of PMVG in this subgroup was low (10%), it was diagnosed in a few cases. This suggests that, PI in coincidence with PMVG can also have benign and reversible causes, and both radiologists and surgeons should be familiar with these [15], highlighting the need for further large-scale studies to identify the aetiology of “benign” / i.e. reversible PI and PMVG. Subsequently, we evaluated a comprehensive risk profile for each patient retrospectively to understand and investigate factors associated with increased mortality as opposed to “benign”/reversible cases. First, we analysed factors associated with decreased survival rates. In line with the low platelet count. Platelets play a central role in the regulation of blood flow and thrombogenic cascades [27]. An increased platelet count was thought to be directly associated with increased vascular inflammation and thrombogenicity and therefore to correlate with thrombotic events like ischemic stroke and myocardial infarction [27, 28]. Conversely, in this study, a low platelet count was associated with a worse prognosis. It is possibly even more interesting to investigate factors that correlate with “benign” PI to identify those patients who do not require surgery but conservative treatment. In our study, low CRP levels, the absence of PMVG, sepsis and COPD were predictive for reversible PI.

When combining the significant parameters identified in the logistic regression model (PMVG, COPD, sepsis and low platelets) to predict a fatal outcome in surgically treated patients, our multivariate model reached a specificity of over 90%. This statistically validated risk profile could serve as a decision support tool to identify patients who are unlikely to benefit from surgery, and thus potentially reducing overtreatment.

Limitations
Our study has several limitations. First and foremost, the retrospective study design and the fact that all readers were aware of this design, introduce a potential detection bias. Secondly, there is an inherent selection bias, as the RIS were searched for reports containing PI and PI-related terms. Hence, if none of these terms were mentioned in the radiology report, the patient was not included. As a diagnosis of PI does not require an arterial contrast phase, not all of the included patients received a CT scan comprising that phase. This can limit the chances of detecting decreased bowel wall enhancement and therefore explain why ischemia did not significantly correlate to the pathology results in all patients undergoing surgery. Also, the medical history was incomplete in some patients. Although pathological reports were available in surgically treated patients they did not provide 100% specificity, which is a further potential cause of distortion.

Conclusion
PI is not necessarily associated with intestinal ischemia but may be attributed to various other causes. The coincidence of PI and PMVG remains indicative of intestinal ischemia and strongly correlates with significantly increased mortality rates. The validated risk profile we introduce can serve as an ancillary decision-making tool to identify patients who are unlikely to benefit from surgery and to potentially reduce overtreatment.

Abbreviations
CRP: C-reactive protein; COPD: Chronic obstructive lung disease; CT: Computed tomography; IMA: Inferior mesenteric artery; OS: Overall Survival; PCT: Procalcitonin, PI: Pneumatosis intestinalis; PMVG: Porto-mesenteric venous gas; RIS: Radiological information system; SMA: Superior mesenteric artery.

Acknowledgements
The project was part of the Doctoral Thesis from Annika Gropp. Dr. med. Timo A. Auer is participant in the BH-Chanité Clinician Scientist Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health.

Authors’ contributions
MDS: Data analysis and conceptualization. RK: Data curation, conceptualization and writing the draft. DPdS: Data curation, conceptualization and writing the draft. EL: Data curation. TAA: Data analysis, conceptualization and writing the draft. FH, JH, AG, DG: Data analysis. JP, BH: Data curation. TAA: Data analysis, conceptualization and writing the draft. RK and MDS officiated as corresponding authors. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Our institutional review board (Charité Ethics Committee, Chanité—University Medicine Berlin) approved this retrospective study (Internal Registration Number EA2/238/17) and waived informed consent due to its retrospective nature. The study protocol conforms to the ethical guidelines of the 2002 Declaration of Helsinki.

Consent for publication
Not applicable.
Competing interests
None.

Author details
1 Department for Radiology, Charité - University Medicine Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. 2 Department for Radiology, University Hospital Mainz, Mainz, Germany. 3 Department for Radiology, University Hospital of Cologne, Cologne, Germany. 4 Department of General, Visceral and Transplant Surgery, Charité – University Medicine Berlin, Berlin, Germany. 5 Berlin Institute of Health (BIH), Berlin, Germany.

Received: 4 January 2021   Accepted: 26 July 2021
Published online: 24 August 2021

References
1. St Peter SD, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. Arch Surg. 2003;138(1):68–75.
2. Wu LL, Yang YS, Dou Y, Liu QS. A systematic analysis of pneumatosis cystoides intestinalis. World J Gastroenterol. 2013;19(30):4973–8.
3. Paran H, Epstein T, Gutman M, Shapiro Feinberg M, Zissin R. Mesenteric and portal vein gas: computerized tomography findings and clinical significance. Dig Surg. 2003;20(2):127–32.
4. Shuck JM, Malan LJ, Hammar MD. Pneumatosis cystoides intestinales due to blunt abdominal trauma. J Trauma. 1974;14(5):435–40.
5. Kelly BS Jr, Meyers P, Choe KA, Hurst J, Luchette FA. Traumatic pneumatosis cystoides intestinales with portal venous air embolism. J Trauma. 1997;42(1):112–4.
6. Yale CE, Balish E, Wu JP. The bacterial etiology of pneumatosis cystoides intestinales. Arch Surg. 1974;109(1):89–94.
7. Jona JZ. Benign pneumatosis intestinales coli after blunt trauma to the abdomen in a child. J Pediatr Surg. 2000;35(7):1109–11.
8. Keyting WS, McCarver RR, Kovarik JL, Daywitt AL. Pneumatosis intestinales: a new concept. Radiology. 1961;67:733–41.
9. Knechtle SJ, Davidoff AM, Rice RP. Pneumatosis intestinalis. Surgical management and clinical outcome. Ann Surg. 1990;212(2):160–5.
10. Shah A, Al Furajii H, Cahill RA. Symptomatic pneumatosis intestinalis (including portal venous gas) after laparoscopic total colectomy. World J Gastrointest Endosc. 2014;6(1):564–7.
11. Wiesner W, Mortele KJ, Glickman JN, Ji H, Ros PR. Pneumatosis intestinalis and portomesenteric venous gas in intestinal ischemia: correlation of CT findings with severity of ischemia and clinical outcome. AJR Am J Roentgenol. 2001;177(6):1319–23.
12. Takase A, Akuzawa N, Naitoh H, Aoki J. Pneumatosis intestinalis with a benign clinical course: a report of two cases. BMC Res Notes. 2017;10(1):319.
13. Jamart J. Pneumatosis cystoides intestinales. A statistical study of 919 cases. Acta Hepatogastroenterol. 1979;26(5):419–22.
14. Gagliardi G, Thompson IW, Hershman MJ, Forbes A, Hawley PR, Talbot IC. Pneumatosis coli: a proposed pathogenesis based on study of 25 cases and review of the literature. Int J Colorectal Dis. 1996;11(3):111–8.
15. Ho LM, Paulson EK, Thompson WM. Pneumatosis intestinalis in the adult: benign to life-threatening causes. AJR Am J Roentgenol. 2007;188(6):1604–13.
16. Fenton LZ, Buonomo C. Benign pneumatosis in children. Pediatr Radiol. 2000;30(11):786–93.
17. Feckzo PJ, Mezwa DG, Farah MC, White BD. Clinical significance of pneumatosis of the bowel wall. Radiographics. 1992;12(6):1069–78.
18. Hussain A, Mahmood H, El-Hasani S. Portal vein gas in emergency surgery. World J Emerg Surg. 2008;3:21.
19. Iannitti DA, Gregg SC, Mayo-Smith WW, Tomolonis RJ, Cioffi WG, Piccolo VE. Portal venous gas detected by computed tomography: is surgery imperative? Dig Surg. 2003;20(4):306–15.
20. T.T. R Foundation for Statistical Computing, Vienna, Austria / https://www.R-project.org/ 2015.
21. T.T. A Package for Survival Analysis in S. version 2.38, https://CRAN.R-project.org/package=survival (R Core Team, Vienna, Austria). 2015.
22. Treyaud MO, Duran R, Zims K, Knebel JF, Meuli RA, Schmidt S. Clinical significance of pneumatosis intestinalis: correlation of MDCT-findings with treatment and outcome. Eur Radiol. 2017;27(1):70–9.
23. Hawn MT, Canon CL, Lockhart ME, Gonzalez QH, Shore G, Bondona A, et al. Serum lactic acid determines the outcomes of CT diagnosis of pneumatosis of the gastrointestinal tract. Am Surg. 2004;70(1):19–23 (discussion 4).
24. DuBose JJ, Lissauer M, Maung AA, Piper GL, O’Callaghan TA, Luo-Owen X, et al. Pneumatosis Intestinalis Predictive Evaluation Study (PIVES): a multicenter epidemiologic study of the Eastern Association for the Surgery of the Trauma. J Trauma Acute Care Surg. 2013;75(1):15–23.
25. Ferrada P, Callcut R, Bausa G, O’Bosky KR, Luo-Owen X, Mansfield NJ, et al. Pneumatosis Intestinalis Predictive Evaluation Study: a multicenter epidemiologic study of the American Association for the Surgery of the Trauma. J Trauma Acute Care Surg. 2017;82(3):451–60.
26. Lassandro F, Mangoni di Santo Stefano ML, Porto AM, Grassi R, Scaglione M, Rotondo A. Intestinal pneumatosis in adults: diagnostic and prognostic value. Emerg Radiol. 2010;17(5):361–5.
27. Altintoprak F, Arslan Y, Yalkin O, Uzunoglu Y, Ozkan OV. Mean platelet volume as a potential prognostic marker in patients with acute mesenteric ischemia- retrospective study. World J Emerg Surg. 2013;8(1):49.
28. Altintoprak F, Arslan Y, Yalkin O, Uzunoglu Y, Ozkan OV. Mean platelet volume as a potential prognostic marker in patients with acute mesenteric ischemia- retrospective study. World J Emerg Surg. 2013;8(1):49.
29. Atkinson R, Elamin A, King SA, Raiskii J, Hasler RJ, Greenberg R, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011;31(5):1215–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions